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Abstract A RIP-like protein, RIP3, has recently been reported
that contains an N-terminal kinase domain and a novel C-
terminal domain that promotes apoptosis. These experiments
further characterize RIP3-mediated apoptosis and NF-UB
activation. Northern blots indicate that rip3 mRNA displays a
restricted pattern of expression including regions of the adult
central nervous system. The rip3 gene was localized by
fluorescent in situ hybridization to human chromosome
14q11.2, a region frequently altered in several types of neoplasia.
RIP3-mediated apoptosis was inhibited by Bcl-2, Bcl-xL,
dominant-negative FADD, as well as the general caspase
inhibitor Z-VAD. Further dissection of caspase involvement in
RIP3-induced apoptosis indicated inhibition by the more specific
inhibitors Z-DEVD (caspase-3, -6, -7, -8, and -10) and Z-
VDVAD (caspase-2). However, caspase-1, -6, -8 and -9
inhibitors had little or no effect on RIP3-mediated apoptosis.
Mutational analysis of RIP3 revealed that the C-terminus of
RIP3 contributed to its apoptotic activity. This region is similar,
but distinct, to the death domain found in many pro-apoptotic
receptors and adapter proteins, including FAS, FADD, TNFR1,
and RIP. Furthermore, point mutations of RIP3 at amino acids
conserved among death domains, abrogated its apoptotic activity.
RIP3 was localized by immunofluorescence to the mitochondrion
and may play a key role in the mitochondrial disruptions often
associated with apoptosis.
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1. Introduction
Tumor necrosis factor-receptor 1 (TNF-R1) and Fas/Apo-
1/CD95 are prototypic members of a family of cell surface
receptors that modulate physiological processes such as in-
£ammation, immunoregulation, and anti-viral responses
through the regulation of apoptosis, a genetically controlled
process of cell suicide [1]. Apoptosis triggered by these recep-
tors is dependent on a conserved cytoplasmic region of about
80 amino acids termed the ‘death domain’ that recruits of
other death domain adapter proteins, such as TRADD,
FADD, and RIP to the receptor complex. This subsequently
leads to the activation of cysteine proteases, or caspases,
which play a critical role in apoptosis by cleaving proteins
involved in the disassembly of the cell structures. In addition
to triggering an apoptotic signal, TNF-K also induces the
activation of the transcription factor, NF-UB, which plays a
critical role in regulating in£ammatory responses [1]. Tran-
scriptional regulation by NF-UB can suppress TNF-K-induced
apoptosis and may be the dominant pathway following TNF-
K treatment. In fact, many cells require the presence of RNA
or protein synthesis inhibitors to elicit TNF-K-mediated apo-
ptosis, suggesting that additional cellular signals are required
for apoptosis to predominate in response to TNF-K.
RIP [2^4], and related proteins, RIP2/RICK/CARDIAK
[5^7], and RIP3 [8,9], are serine/threonine kinases that con-
tribute to both TNF-K-mediated apoptosis and NF-UB acti-
vation. The process of RIP-mediated apoptosis involves bind-
ing to the adapter molecule RAIDD/CRADD [10,11].
RAIDD contains a death domain, involved in the interaction
with RIP, and a caspase recruitment domain (CARD), which
binds to and activates caspase-2. The CARD domain is struc-
turally similar to the death domain and is involved in self-
association with other CARD domains found in the pro-do-
main of some caspases [12,13]. Thus, RIP interaction with
RAIDD leads to the binding and activation of caspase-2 trig-
gering a caspase cascade similar to, but likely distinct from,
that initiated by caspase-8 through FADD. Like RIP, RIP2
contains a kinase domain, but instead of a death domain,
RIP2 contains a CARD domain. RIP2 does not interact
with RAIDD, but instead activates caspase-8 and caspase-1
through the CARD domain. RIP3 was identi¢ed based on
homology and interaction with RIP, and like the related pro-
teins it contains an N-terminal kinase domain. RIP3 also has
a unique C-terminus that contributes to apoptosis and bind-
ing to RIP. These experiments further dissect the role of RIP3
in apoptosis and NF-UB activation.
2. Materials and methods
2.1. Identi¢cation of RIP3 and generation of expression constructs
RIP3 was identi¢ed from a homology search of the proprietary
Incyte Lifeseq database with death domain containing kinases, RIP
and Pelle, using the BLAST algorithm. Two Incyte clones were de-
tected (accession numbers 1626570 and 2301422). Clone number
2301422 was veri¢ed to contain the full-length mRNA and included
an in-frame stop codon in the 5P-untranslated regions (UTR). The
coding sequence of wild-type and mutant (K50A, W434A/W477A,
and vC420) RIP3 constructs were sub-cloned into pTracer-SV-40 (In-
vitrogen, Carlsbad, CA, USA) containing the green £uorescent pro-
tein (GFP) marker. Sub-cloning was performed by polymerase chain
reaction (PCR) from Incyte clone 2301422 using the Advantage HF
PCR kit (Clontech, Palo Alto, CA, USA) and then ligated into the
EcoRV/NotI sites in pTracer-SV-40. The plasmids encoding a C-ter-
minal hemagglutinin (HA)-tagged RIP3 and K50A were prepared by
PCR and ligated into the KpnI/NotI sites in the vector, pMH (Boehr-
inger Mannheim, Indianapolis, IN, USA). Human RIP was cloned by
PCR from a human monocyte cDNA library (Clontech, Palo Alto,
CA, USA) and also ligated into pMH via HindIII/EcoRI sites. The
human bax gene was obtained from Incyte (accession number
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3334311) and sub-cloned into the EcoRV/NotI sites in pTracer-SV-40.
Human bcl-xL and bcl-2 were also obtained from Incyte (accession
numbers 1855683 and 395314 respectively) and cloned into the mam-
malian expression vector pZeo-SV2 (Invitrogen, Carlsbad, CA, USA)
driven by the SV-40 promoter and lacking the GFP marker. Domi-
nant-negative FADD was designed as reported previously [14] lacking
the N-terminal death e¡ector domain (amino acids 1^79) and was
prepared by PCR from Incyte clone 2057308 and ligated into the
EcoRI/NotI sites in pZeo-SV2. The nucleotide sequences of all of
the clones were con¢rmed by £uorescent terminator cycle sequencing
using an automated 377 DNA sequencer (Perkin-Elmer, Applied Bio-
systems, Foster City, CA, USA).
2.2. Northern blotting
Northern blots (Clontech, Palo Alto, CA, USA) containing human
poly-A RNA (2 Wg per lane) prepared from various adult human
tissues were hybridized to random primed radiolabeled rip3 or actin
cDNAs. Hybridizations were performed with Hybrisol I (Oncor, Gai-
thersburg, MD, USA) incubated overnight at 42‡C. The blots were
washed with 2USSC+0.05% SDS at room temperature followed by
high stringency washing, 0.1USSC+0.1% SDS at 50‡C. Blots were
visualized using a Phosphorimager (Molecular Dynamics, Sunnyvale,
CA, USA).
2.3. Fluorescent in situ hybridization (FISH)
The sub-chromosomal location of rip3 was determined by PCR
screening of a human genomic library in a bacterial arti¢cial chromo-
some (BAC) vector (Genome Systems, St. Louis, MO, USA) using
primers 5P-TGGTATAATCATAGCGGGA-3P (positions 1744^1762)
and 5P-AGCATTCCATCATGTTTAT-3P (positions 1898^1916). Pos-
itive BAC clones were sequenced to con¢rm the presence of rip3 and
subsequently labeled with digoxigenin-dUTP by nick translation and
used in FISH. FISH was performed from metaphase chromosomes
derived from PHA stimulated peripheral blood leukocytes (PBL) in a
solution containing 50% formamide, 10% dextran sulfate and 2USSC.
Speci¢c hybridization signals were detected by incubating the slides in
£uoresceinated anti-digoxigenin antibodies followed by counterstain-
ing with DAPI.
2.4. Laser scanning cytometric analysis of cell death
HeLa cells (ATCC, Rockville, MD, USA) were cultured in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and penicillin (100 U/ml)/streptomycin (0.1 mg/
ml) and maintained at 37‡C/5% CO2. Transient transfections were
performed using the Lipofectamine Plus system (Life Technologies,
Grand Island, NY, USA) according to manufacturer’s speci¢cations.
Stock solutions (100 mM) of the caspase inhibitors, Z-VAD-FMK, Z-
DEVD-FMK, Z-IETD-FMK, Z-VEID-FMK, and Z-VDVAD-FMK
(Enzyme Systems, Livermore, CA, USA) were prepared in DMSO
and added to the cultures 3 h post-transfection (200 WM ¢nal volume).
Twenty-four hours post-transfection the cells were ¢xed with 2% para-
formaldehyde in PBS, counterstained with 10 Wg/ml propidium iodide,
200 Wg/ml RNase A, and 0.1% Tween-20 for 30 min at room temper-
ature, and then mounted with Immu-mount (Shandon, Pittsburgh,
PA, USA). A laser scanning cytometer (LSC; CompuCyte, Cam-
bridge, MA, USA) was used to determine the percent of GFP-positive
cells. The propidium iodide staining served as a marker required for
gating the cell population. Relative £uorescence values were deter-
mined with an excitation at 488 nm using an argon laser and emission
¢lters at 505^540 nm (GFP) and 614^639 nm (propidium iodide).
Staining was con¢rmed by microscopically re-locating cells within
the gated regions.
2.5. Immuno£uorescence
HeLa cells grown on coverslips were transfected with pMH-rip3,
pMH-rip, or empty pMH vector, encoding a C-terminal HA tag.
Transfectants were incubated with the caspase inhibitors Z-DEVD-
FMK and Z-VAD-FMK (200 WM) to inhibit apoptosis. Twenty-four
hours post-transfection the cells were incubated with the mitochon-
drial dye, Mitotracker Red CMXRos (500 nM; Molecular Probes,
Eugene, OR, USA) for 20 min at 37‡C. The cells were then ¢xed
with 2% paraformaldehyde and permeabilized with 0.2% Triton
X-100 in PBS. Coverslips were incubated with a mouse monoclonal
antibody against the HA tag (Boehringer Mannheim, Indianapolis,
IN, USA) for 1 h at 37‡C. Co-staining with NF-UB was performed
using a rabbit polyclonal antibody against NF-UB (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA). Treatment with TNF-K
(1500 U/ml; Calbiochem, La Jolla, CA, USA) for 5 h served as a
positive control for the nuclear translocation of NF-UB. Staining for
the HA-tagged proteins and NF-UB were detected using FITC-con-
jugated goat anti-mouse (Life Technologies, Grand Island, NY, USA)
and Cy-3-conjugated goat anti-rabbit antibodies (Jackson Immunore-
search, West Grove, PA, USA) incubated for 1 h at 37‡C. The cells
were visualized by epi£uorescence using an Olympus AX70 micro-
scope equipped with a Sony DKC-5000 CCD camera (Hitech Instru-
ments, Inc., Edgemont, PA, USA).
3. Results and discussion
3.1. Identi¢cation, expression, and chromosomal localization of
rip3
We identi¢ed the rip3 cDNA through BLAST searches of a
proprietary (Incyte) database for homologues to RIP family
of death-promoting kinases. The nucleotide sequence was
identical to that recently reported for rip3 and encoded a
518 amino acid protein containing an N-terminal serine/threo-
nine kinase domain between amino acids 1 and 279 [18,19].
The clone contained an in-frame stop codon in the 5P-untrans-
lated region (UTR) suggesting that it encoded a full-length
protein.
The tissue distribution of rip3 was determined by Northern
blotting with mRNA prepared from 16 di¡erent adult human
tissues. Using the entire cDNA coding sequence of rip3 as a
probe, two distinct mRNAs of approximately 2.1 kb and
2.6 kb were detected (Fig. 1). The shorter of these transcripts
Fig. 1. Expression of rip3. Northern blots were performed from
commercially available multiple tissue and CNS blots (Clontech).
Each lane contains 2 Wg of poly-A RNA. Blots were probed with
a cDNA sequence containing the entire coding region of rip3. Two
transcripts were identi¢ed at 2.0 and 3.5 kb. The loading e⁄ciency
and quality of the RNA were monitored by actin hybridization.
PBL, peripheral blood leukocytes.
FEBS 23608 11-5-00 Cyaan Magenta Geel Zwart
G.M. Kasof et al./FEBS Letters 473 (2000) 285^291286
was consistent with the identi¢ed full-length clone from the
Incyte database. The nature of the larger transcript is still
unknown. Expression of rip3 was observed in the heart, brain,
placenta, skeletal muscle, kidney, pancreas, spleen, and PBL.
In addition, the 2.1 kb rip3 transcript was detected at low
levels within the prostate, testis, and colon. We were unable
to detect rip3 in the lung, liver, thymus, ovary, and small
intestine, although previous reports have shown expression
in the lung and liver [9]. To investigate the expression pattern
of rip3 in more detail, we probed several cancer cell lines as
well as speci¢c regions within the central nervous system
(CNS). The rip3 mRNA was not detected by Northern blot
in any of 23 cancer lines examined, although it could be de-
tected by RT-PCR in some cases (data not shown). However,
analysis of rip3 levels within the CNS did reveal some expres-
sion, particularly the smaller transcript, in several regions,
including the subthalamic nucleus, substantia nigra, corpus
callosum, putamen, spinal cord, and medulla suggesting a
specialized role of RIP3 in these structures (Fig. 1). Thus,
expression of rip3 was restricted in a tissue speci¢c manner.
Furthermore, the pattern of rip3 expression was di¡erent to
that reported for rip and rip2 suggesting that tissue speci¢city
may provide distinct roles for these related genes [2,4,5].
To further investigate a link between rip3 and disease, the
chromosomal location of rip3 was determined by FISH. PCR
primers containing the 3P-UTR of rip3 were used to screen a
human genomic BAC library which was then used as a probe
for FISH analysis. A single FISH signal at 14q11.2 was de-
tected in 14 of 15 metaphase spreads from human chromo-
somes (data not shown). Lesions at this chromosomal locus
are frequently associated with several types of cancer, partic-
ularly nasopharyngeal carcinoma [15] and several leukemias/
lymphomas [16^18]. This is consistent with the lack of rip3
expression in any of 23 cancer cell lines that we examined.
Further investigation will be required to determine the role of
RIP3 in tumor progression and/or maintenance.
3.2. RIP3-mediated apoptosis in HeLa cells
Previous studies have shown that overexpression of RIP3,
like RIP and RIP2, can induce cell death [18,19]. We at-
tempted to extend these results by analyzing the apoptotic
activity of some missense and deletion mutants of RIP3 as
well as evaluating the e¡ects of potential apoptotic inhibitors.
Wild-type and mutant rip3 were cloned into the GFP contain-
ing vector pTracer-SV-40. The percent of GFP-positive cells,
determined with a laser scanning cytometer, provided an in-
dication of relative viability. Viability in RIP3 transfected cells
was reduced to V26% as compared to an empty pTracer-SV-
40 vector (Table 1). The apoptotic activity of RIP3 was com-
parable to the pro-apoptotic Bcl-2 family member, Bax (Table
1). RIP3 transfected cells also produced an increase in TU-
NEL staining indicating that these cells were dying apoptosis
Table 1
Characterization of Rip3-mediated apoptosis
Treatment % Relative viability
pTracer-SV-bax 26.6 þ 8.2
pTracer-SV-40-rip3 26.7 þ 3.0
pTracer-SV-40-rip3-K50A 24.9 þ 4.5
pTracer-SV-40-rip3-vC421 51.4 þ 1.4
pTracer-SV-40-rip3-W435A, W478A 71.8 þ 2.3
pTracer-SV-40-rip3+pZeo 22.8 þ 1.1
pTracer-SV-40-rip3+pZeo-bcl-2 69.5 þ 3.6
pTracer-SV-40-rip3+pZeo-bcl-xL 68.8 þ 11.2
pTracer-SV-40-rip3+pZeo-FADD-DN 54.5 þ 3.2
pTracer-SV-40-rip3+DMSO 18.7 þ 3.0
pTracer-SV-40-rip3+Z-VAD-FMK 50.0 þ 0.8
pTracer-SV-40-rip3+Z-DEVD-FMK 35.0 þ 6.2
pTracer-SV-40-rip3+Z-IETD-FMK 22.8 þ 4.3
pTracer-SV-40-rip3+Z-VEID-FMK 20.3 þ 10.0
pTracer-SV-40-rip3+Z-VDVAD-FMK 39.4 þ 5.4
HeLa cells (2U105) were transfected with 1 Wg of pTracer-SV-40 de-
rived plasmids containing bax, rip3, mutants vC420, K50A, or
W434/W47, or empty vector. Inhibition studies were performed by
co-transfecting 1 Wg of pTracer-SV-40-rip3 with 1 Wg of bcl-2, bcl-
xL, FADD-DN or the empty pZeo vector. Also as indicated
pTracer-SV-40-rip3 transfected cells were incubated with 200 WM of
the caspase inhibitors, Z-VAD-FMK, Z-DEVD-FMK, Z-IETD-
FMK, Z-VEID-FMK, Z-VDVAD-FMK, or 0.2% DMSO control.
Twenty-four hours post-transfection the cells were ¢xed and the per-
cent of GFP-positive cells was determined by laser scanning cyto-
metry. At least 6000 cells were counted for each sample. The per-
cent relative viability is the percent of GFP-positive cells compared
to empty vector controls (pTracer-SV-40 with or without DMSO).
N = 3.
Fig. 2. Homology of the C-terminus of RIP3 with death domains. Shown here are the alignments of RIP3 with other known death domains
containing proteins generated using the Clustal algorithm from the MegAlign software (DNA Star). Dark shading indicates identical residues
among family members, while lighter shading represents similar amino acids.
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(data not shown). Disruption of RIP3-mediated kinase activ-
ity by amino acid substitution of the putative ATP-binding
site, lysine to alanine at position 50 (K50A) [8,9], had no e¡ect
on RIP3-triggered apoptosis (Table 1). In contrast, both mis-
sense and deletion mutations within the C-terminus signi¢-
cantly attenuated its apoptotic activity. A deletion mutant
lacking amino acids 422^519 (vC420) decreased RIP3 apo-
ptotic activity. Indeed, the C-terminus of RIP3 previously
was shown to contribute to apoptosis and interaction with
death domain containing proteins [8,9]. This region of RIP3
has some homology to death domains which may explain its
apoptotic activity as well as its ability to bind to other death
domain containing proteins (Fig. 2). The C-terminal region of
RIP3 contains several residues, which by mutagenesis of Fas
and TNF-R1, were shown to be critical for death domain
interactions and cytotoxicity like the tryptophan residue at
position 477, the leucine residues at 474 and 488 [12]. RIP3
also contains several highly conserved residues like trypto-
phan 434, valine 444, threonine 445, leucine 449, and isoleu-
cine 452. The conserved valine residue at position 444 of RIP3
is the site of a naturally occurring mutation within Fas that
leads to lymphoproliferation syndrome in mice [19]. However,
RIP3 does not contain several highly conserved residues
which were critical for either Fas or TNF-R1 function, such
as arginine 376, leucine 378, alanine 416, and leucine 421
(positions corresponding to TNF-R1). In addition, RIP3 con-
tains several proline residues which may disrupt the K-helical
structure of the death domain. Thus, it is unlikely that RIP3
forms a typical death domain structure. Nonetheless, to de-
termine if this region could function similar to a death do-
Fig. 3. Sub-cellular localization of RIP3. HeLa cells (2U105) were transfected with 1 Wg of pMH-rip3 or pMH-rip plasmids which contain HA
epitope tags. Transfected cells were incubated with 200 WM of the caspase inhibitors Z-VAD-FMK or Z-DEVD-FMK. Twenty-four hours
post-transfection, the cells were incubated with Mitotracker Red CMX (500 nM) for 20 min at 37‡C and then immuno-stained using a mouse
monoclonal HA antibody followed by a FITC-conjugated goat anti-mouse antibody. Micrographs (60U objective) show epitope staining of
RIP/RIP3 (left), Mitotracker staining (middle), and a composite of the two panels performed using Adobe Photoshop (right).
FEBS 23608 11-5-00 Cyaan Magenta Geel Zwart
G.M. Kasof et al./FEBS Letters 473 (2000) 285^291288
main, a point mutant was made with double amino acid sub-
stitutions of the conserved tryptophans 434 and 478 (W434/
W478) and was found to have reduced apoptotic activity. This
raises the possibility that the C-terminus of RIP3 can have a
biochemical role analogous to other death domains.
To address the mechanism of RIP3-mediated apoptosis, the
e¡ects of known apoptotic inhibitors were examined. The
anti-apoptotic Bcl-2 family members, Bcl-2 and Bcl-xL, which
inhibit apoptosis triggered by many stimuli, were capable of
blocking RIP3-mediated apoptosis. This suggests that RIP3
functions upstream to Blc-2 family members in apoptotic sig-
naling (Table 1). Co-expression of dominant-negative FADD
(FADD-DN), which inhibits the apoptotic pathways initiated
by TNF-K, Fas, and RIP [14,20,21], also suppressed apoptosis
triggered by RIP3 (Table 1). The dependence of caspases on
RIP3-mediated apoptosis was tested using both general and
speci¢c caspase inhibitors. The general caspase inhibitor Z-
VAD was capable of suppressing RIP3-mediated apoptosis.
More speci¢c caspase inhibitors developed based upon dis-
tinct preferences in their cleavage site have been shown to
be e¡ective at selectively inhibiting caspase activation [22].
Some of these inhibitors were tested here for their ability to
suppress RIP3-mediated apoptosis. The minimally e¡ective
amount of caspase inhibitor was used in order to maintain
selectivity. Inhibition of RIP3 was observed by Z-DEVD, an
inhibitor of caspase-3, -6, -7, -8, and -10, as well as by the
caspase-2 inhibitor, Z-VDVAD (Table 1). In contrast, the
caspase-6 inhibitor Z-VEID and caspase-8 inhibitor Z-IETD
(Table 1) as well as the caspase-1 inhibitor Z-WEHD and the
caspase-9 inhibitor Z-LEHD (data not shown) had little or no
e¡ect on RIP3-mediated apoptosis. Taken together, these data
suggest that some or all of the set of caspases, caspase-2, -3,
-7, and -10, are candidates for RIP3 signaling. These results
appear to be consistent with the pathway involved in RIP-
Fig. 4. RIP3 induction of NF-UB. HeLa cells (2U105) were transfected with 1 Wg of pMH-rip3, pMH-rip or with a control empty pTracer-SV-
40 vector. As a positive control, untransfected cells were treated with 1500 U/ml of TNF-K for 5 h. Twenty-four hours post-transfection, the
cells were immuno-stained with the mouse monoclonal HA antibody as well as a rabbit polyclonal antibody against NF-UB. Staining was visu-
alized using FITC- and Cy-3-conjugated antibodies against mouse and rabbit, respectively. Representative micrographs (60U objective) are
shown for the indicated treatments. Green FITC staining is the HA staining while red Cy-3 staining is the NF-UB staining. Arrow bars point
to co-stained cells.
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mediated apoptosis which includes activation of caspase-2
through interaction with RAIDD [10,11]. However, both
RIP [3,4] and its downstream e¡ector, caspase-2 [23] are not
required for TNF-K- or Fas-mediated apoptosis. This raises a
question as to the physiological signi¢cance of the RIP family.
One possibility is that they enhance the dominant FADD/
caspase-8 pathway triggered by TNF-K. Thus, activation of
caspase-2 via the RIP/RAIDD interaction provides additive
signaling for apoptosis. However, it is also reasonable that the
RIP family members play a more critical role in other death
receptor-mediated cytotoxicity, such as DR5 and DR6, whose
signaling pathways leading to cell death are largely unknown.
3.3. Sub-cellular localization of RIP3
To determine the sub-cellular localization of RIP3, the HA-
tagged vector (pMH-rip3) was transfected into HeLa cells.
Cells were maintained in the presence of the caspase inhibitors
Z-VAD or Z-DEVD to protect them from apoptosis. Staining
was performed by indirect immuno£uorescence using a mouse
monoclonal antibody against the HA epitope followed by a
secondary FITC-conjugated goat anti-mouse antibody. HA-
RIP3 was detected predominantly in a punctate pattern within
the cytoplasm (Fig. 3) similar to that previously reported for
RIP [2]. To investigate this in more detail, the staining was
performed in conjunction with £uorescent markers for distinct
sub-cellular organelles. No co-localization of RIP3 with the
endoplasmic reticulum or Golgi apparatus was detected using
the dyes Concanavalin A and wheat germ agglutinin (data not
shown). However, RIP and RIP3 did co-localize with the
mitochondrial selective dye, Mitotracker, which penetrates
and stains functional mitochondria (Fig. 3). The similar local-
ization of RIP and RIP3 is also consistent with their ability to
interact [8,9] and suggests that the RIP^RIP3 interaction oc-
curs at the mitochondrion.
The uptake of Mitotracker is dependent on the mitochon-
drion’s activity which is often compromised during apoptosis.
Caspase activation may occur both upstream or downstream
of the loss of mitochondrial membrane potential [24]. Here,
we observed in the presence of the general caspase inhibitor Z-
VAD, RIP/RIP3 expressing cells had normal Mitotracker
staining suggesting that RIP and RIP3 can activate caspases
that are upstream of the mitochondrial events. To determine
whether RIP and RIP3 were capable of disrupting mitochon-
drial activity, a more speci¢c caspase inhibitor, Z-DEVD, was
used. In the presence of Z-DEVD, RIP3 (Fig. 3) and RIP
(data not shown) were still present in the punctate cytoplasmic
regions. However, the Mitotracker staining in regions where
RIP3 appeared to be more intense had disappeared. Thus the
levels of RIP3 at the mitochondrion directly correlate with
mitochondrial integrity suggesting a role for RIP3 in this
part of the apoptotic process. Furthermore, the e¡ects of
RIP3 on the mitochondrion are vulnerable to Z-VAD, but
not Z-DEVD-sensitive caspases. Interestingly, caspase-2 is
one of the caspases normally found in the mitochondria and
released upon apoptosis [25], which raises the possibility that
RIP/RIP3 interaction with a RAIDD-like protein activates
caspase-2 directly at the mitochondria rather than at the
TNF receptor complex.
3.4. RIP3 induces NF-UB nuclear translocation
The ability of RIP3 to stimulate NF-UB activity has been
somewhat controversial. Initial reports indicated that overex-
pression of RIP3 stimulated an NF-UB receptor construct [8].
Subsequently, it was found that RIP, but not RIP3 could
induce NF-UB and that RIP3 could inhibit RIP-mediated
NF-UB activation [9]. To help resolve this controversy, we
examined the ability of RIP and RIP3 to translocate NF-UB
from the cytoplasm to the nucleus. NF-UB is normally seques-
tered in the cytoplasm through an interaction with the inhib-
itory protein, I-UB. Phosphorylation of I-UB leads to its deg-
radation by proteasomes resulting in the translocation of NF-
UB to the nucleus. HeLa cells were transfected with vectors
expressing either HA-RIP or HA-RIP3 and immuno-stained
using both a mouse monoclonal HA antibody as well as a
rabbit polyclonal antibody against NF-UB. As a positive con-
trol, we showed that treatment with TNF-K e¡ectively in-
duced NF-UB translocation (Fig. 4). Furthermore, overexpres-
sion of RIP induced NF-UB translocation in nearly all cells.
RIP3, while not as potent as RIP, was still able to induce an
increase in NF-UB nuclear translocation in about 50% of
transfected cells. Untransfected cells, or cells transfected
with an empty vector (pTracer-SV-40), showed relatively little
NF-UB translocation (about 10%). These results clearly indi-
cate that at a single cell level, overexpression of RIP3 is able
to stimulate NF-UB and in summary highlight the dual func-
tions of RIP3 in apoptosis and NF-UB activation.
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